Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer

Ítems similars

• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
  per: Emanuele Perrone, et al.
  Publicat: (2020-03-01)
• Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
  per: Perrone, Emanuele, et al.
  Publicat: (2020)
• NOVEL ANTIBODY-DRUG CONJUGATES: CURRENT AND FUTURE ROLES IN GYNECOLOGIC ONCOLOGY
  per: Tymon-Rosario, Joan, et al.
  Publicat: (2021)
• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
  per: Zeybek, Burak, et al.
  Publicat: (2020)
• Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
  per: Lopez, Salvatore, et al.
  Publicat: (2020)